4SC AG
4SC Commences Phase II Trial in Hepatocellular Carcinoma HCC with the HDAC Inhibitor 4SC-201
Published in Healthcare Mergers, Acquisitions and Ventures Week, September 5th, 2009
4SC AG (Frankfurt, Prime Standard: VSC) the German drug discovery and development company, announced the dosing of the first patient in its Phase II trial with 4SC-201 (resminostat), a pan-histone deacetylase (HDAC) inhibitor, as a new potential treatment option for patients with advanced hepatocellular carcinoma (HCC), the most frequent form of liver cancer. This proof-of-concept (POC) study will evaluate 4SC-201 as a second line therapy in this indication, for which only a single first line therapy drug is currently approved.
The 'Shelter' study, entitled 'A proof-of-concept Phase II study to evaluate efficacy, safety and pharmacokinetics of 4SC-201 and of the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- "Slicing the Ct Market: Next Generation, 64, and 16". www.KLASresearch.com. May 2009. Klas Confi
Siemens Emotion CT Receives Top Rating in KLAS Report - 1-800-Radiator
1-800-Radiator Offering Free Replacement Radiator or A/C Part After Car Warranty Expires to Supplement Cash for Clunkers Program - 27th Point
27th Point Launches a New Program to Help Start-Up Manufacturers in the Home and Fashion Industry - 360 Public Relations
Renwick Will Lead Healthy Living Practice at 360PR - 360 Systems
Red Sox Find Solid Utility Player in 360 Systems Video Server - 7 Brands, Inc.
Translation Services Made in the U.S. Becoming the First Choice for European Companies, Announces 7 Brands, Inc. - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
